

## MATERIALS LICENSE

Amendment No. 12

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301738

## Licensee

1. Riverview Hospital
2. 395 Westfield Road  
P.O. Box 220  
Noblesville, IN 46060

In accordance with letter dated  
August 13, 1996

3. License Number 13-16286-01 is amended in  
its entirety to read as follows:

4. Expiration Date October 31, 2000

5. Docket or  
Reference No. 030-10729

6. Byproduct, Source, and/or  
Special Nuclear Material7. Chemical and/or Physical  
Form8. Maximum Amount that Licensee  
May Possess at Any One Time  
Under This License

- |   |  |              |
|---|--|--------------|
| A. Any byproduct material identified in 10 CFR 35.100 | A. Any radiopharmaceutical identified in 10 CFR 35.100 | A. As needed |
| B. Any byproduct material identified in 10 CFR 35.200 | B. Any radiopharmaceutical identified in 10 CFR 35.200 | B. As needed |
| C. Any byproduct material identified in 10 CFR 35.300 | C. Any radiopharmaceutical identified in 10 CFR 35.300 | C. As needed |
| D. Any byproduct material identified in 10 CFR 31.11  | D. Prepackaged Kits                                    | D. As needed |

## 9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.
- D. In vitro studies.

9610070064 960923  
PDR ADOCK 03010729  
C PDR

COPY

230 SD

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

13-16286-01

Docket or Reference Number

030-10729

Amendment No. 12

CONDITIONS

10. Location of Use: 395 Westfield Road, Noblesville, Indiana.
11. Radiation Safety Officer: Thomas A. Pence, C.N.M.T.
12. Authorized Users:
- A. Linda Lau, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - B. Farouk E. Mercho, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - C. Michael B. Spence, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - D. Dale Apodaca, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - E. David Brown, M.D. 10 CFR 35.100, 35.200, and 31.11.
  - F. Gonzalo Chua, M.D. 10 CFR 35.100, 35.200 and 31.11.
  - G. Larry Heck, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - H. Jerry Kight, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - I. Paul Peterson, M.D. 10 CFR 35.100, 35.200 and 31.11.
  - J. Barbara Taylor, M.D. 10 CFR 35.100, 35.200 and 31.11.
  - K. Eugene VanHove, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - L. James Stinebaugh, M.D. 10 CFR 35.100, 35.200 and 31.11 for  
nuclear cardiology.
  - M. Bryan Burney, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.
  - N. Fred McFall, M.D. 10 CFR 35.100, 35.200 and 31.11.

COPY

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number


13-16286-01

Docket or Reference Number

030-10729

Amendment No. 12

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letters received May 3, 1990 (with attachments); and June 27, 1996 (except addendum VI); and
- B. Letter dated July 23, 1990 (with attachments).



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

Sept 23, 1996

By

Frederic B. Matton

Nuclear Materials Licensing Branch, Region III

COPY

(FOR LFMS USE)  
INFORMATION FROM LTS

BETWEEN:

License Fee Management Branch, ARM  
and  
Regional Licensing Sections

Program Code: 02120  
Status Code: 0  
Fee Category: 7C  
Exp. Date: 20001031  
Fee Comments:  
Decom Fin Assur Req'd: N

R9

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: RIVERVIEW HOSPITAL  
Received Date: 960819  
Docket No: 3010729  
Control No.: 301738  
License No.: 13-16286-01  
Action Type: Amendment

2. FEE ATTACHED

Amount:  
Check No.: \*

\* ADDL INFO - 301525  
R9

3. COMMENTS

Signed  
Date

D. Hersey  
8-23-96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /X/)

**FEE NOT REQUIRED**

1. Fee Category and Amount

2. Correct Fee Paid. Application may be processed for:

Amendment ☒  
Renewal ☐  
License ☐

3. OTHER

Signed  
Date

SC  
8/27/96

SEP 03 1996

Log	Aug 11 III
Remitter	
Check No.	
Amount	
Fee Category	7C
Type of Fee	Am
Date Check Rec'd	
Date Completed	8/27/96
By	SC

**R**

## Riverview Hospital

August 13, 1996

U.S. Nuclear Regulatory Commission  
Region III  
Materials Licensing Section  
801 Warrenville Road  
Lisle, Illinois 60532

Dear Sirs:

This letter is being submitted as a response to your letter of July 18, 1996. Please refer to your Control #301525.

Please find enclosed the a copy of our a preceptorship for Dr. Spence by Dr. Frank Mercho. The time period covered by this action was from 1990 to 1993. The preceptorship by Dr. Linda Lau was from 1993 to 1996.

The preceptor statement by Dr. Mercho was inadvertently omitted from the amendment request sent June 27, 1996.

Also included with this letter is further documentation of license history for Dr. Fred McFall in license # 13-16622-01 at Culver Union Hospital at Crawfordsville, Indiana.

We wish to apologize for the inconvenience this may have caused your office.



Thomas A. Pence  
Radiation Safety Officer

ADD'L info - 301525  
**FEE NOT REQUIRED**

**RECEIVED**

**AUG 19 1996**

**AUG 19 1996**  
**REGION III**

995 Westfield Road  
P.O. Box 220  
Noblesville, IN 46060  
317-773-0760  
Fax: 317-776-7134

301738



Michael Spence, M.D.

## SUPPLEMENT B

SUPPLEMENT

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME

Michael B. Spence

STREET ADDRESS

11832 Eden Place Dr.

CITY

Carmel,

STATE

In.

ZIP CODE

46032

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
	Thyroid scan		This Preceptoship for I-131 only.
	Thyroid uptake		
	Lung perfusion scan		
	Xenon ventilation study		
	Aerosol ventilation scan		
	Renal flow scan		
	Brain scan		
	Liver/spleen scan		
	Bone scan		
	Gastroesophageal study		
	LeVeen shunt study		
	Cystogram		
	Dacryocystogram		
	Cardiac perfusion scan.		
	Cardiac stress ventriculogram		
	Cardiac rest ventriculogram		
	Gallium scan		

## PROPOSED PHYSICIAN USER

Michael B. Spence, M.D.

## PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	5	
	TREATMENT OF HYPERTHYROIDISM	12	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mn-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION

Riverview Hosp

DATES

CLOCK HOURS OF EXPERIENCE

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE  
WAS OBTAINED UNDER THE SUPERVISION OF:

## a. NAME OF SUPERVISOR

Frank Mercho, M.D.

## b. NAME OF INSTITUTION

Riverview Hospital

## c. MAILING ADDRESS

395 Westfield Rd.

## d. CITY

Noblesville, In. 46060

## e. MATERIALS LICENSE NUMBER(S)

## 5. PRECEPTOR'S SIGNATURE

Frank E. Mercho, MD

## 7. PRECEPTOR'S NAME (Please type or print)

Dr. Frank Mercho

## 8. DATE

3-26-93



FORM NRC-313M-SUPPLEMENT B  
(B-78)

U. S. NUCLEAR REGULATORY COMMISSION

# PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Michael B. Spence

STREET ADDRESS

Riverview Hospital  
395 Westfield Blvd.

CITY

Noblesville,

STATE

Ind.

ZIP CODE

46060

## KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		This preceptor statement is for the addition of I-131 Therapy to Thyroid only.  This physician is currently listed on license # 13-16286-01 as an authorized user.
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

FORM NRC-313M-SUPPLEMENT B  
(B-78)

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloid)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	2	
	TREATMENT OF HYPERTHYROIDISM	5	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		5. PRECEPTOR'S SIGNATURE	
a. NAME OF SUPERVISOR Linda Lau, M.D.		Linda Lau, M.D.	
b. NAME OF INSTITUTION Riverview Hospital			
c. MAILING ADDRESS 395 Westfield Blvd.		7. PRECEPTOR'S NAME (Print type or print)	
d. CITY Noblesville, Ind. 46060		Linda Lau, M.D.	
e. MATERIALS LICENSE NUMBER(S) 13-16286-01		8. DATE 7/23/96	

FORM NRC-313M-SUPPLEMENT B  
(8-78)

Fred McFall, M.D.

NRC FORM 374  
(10-80)

NUCLEAR REGULATORY COMMISSION

1 OF 2 PAGES

**MATERIALS LICENSE**

Amendment No. 07

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

**Licensee**

1. Culver Union Hospital
2. 1710 Lafayette Road  
Crawfordsville, IN 47933

In accordance with letter dated  
September 4, 1991  
3. License number 13-16622-01 is renewed in  
its entirety as follows:

4. Expiration date March 31, 1997

5. Docket or Reference No. 030-11342

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material identified in 10 CFR 35.100

A. Any radiopharmaceutical identified in 10 CFR 35.100

A. As needed

B. Any byproduct material identified in 10 CFR 35.200

B. Any radiopharmaceutical identified in 10 CFR 35.200

B. As needed

C. Any byproduct material identified in 10 CFR 35.300

C. Any radiopharmaceutical identified in 10 CFR 35.300 (excluding Iodine-131 for thyroid carcinoma therapy)

C. As needed

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300 (excluding Iodine-131 for thyroid carcinoma therapy).

CONDITIONS

10. Location of Use: 1710 Lafayette Road, Crawfordsville, Indiana.

11. Radiation Safety Officer: Fred McFall, M.D.

**COPY**

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

13-16622-01

Docket or Reference number

030-11342

Amendment No. 07

## 12. Authorized Users:

- A. Fred McFall, M.D., for material in 10 CFR 35.100 and 35.200.
- B. David Brown, M.D., for material in 10 CFR 35.100 and 35.200.
- C. Paul Peterson, M.D., for material in 10 CFR 35.100 and 35.200.
- D. Larry Heck, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).
- E. Jerry Knight, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).
- F. Gonzalo Chua, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).
- G. Eugene Van Hove, M.D., for material in 10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).

13. Pursuant to Title 10, Chapter I, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

14. In addition to the possession limit in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

15. The licensee shall maintain records of information important to safe and effective decommissioning at the location listed in Item 2. of this license per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

16. This license is based on the licensee's statements and representations listed below:

- A. Letter dated September 4, 1991 with attachments.

For the U.S. Nuclear Regulatory Commission

Original Signed by Patricia M. Vacherio


By

Materials Licensing Section, Region III

Date: MAR 05 1992

COPY





DEPARTMENT OF RADIOLOGY AND  
RADIOLOGICAL SERVICES

1701 North Senate Boulevard

P.O. Box 1367

Indianapolis, IN 46206

Office: (317) 929-8876

Fax: (317) 929-2019

June 17 1993

Tom Pence  
Radiation Safety Officer  
Riverview Hospital  
395 Westfield Blvd.  
Noblesville, IN 46060

Dear Tom:

The following RSI Radiologists have been approved as Authorized Users by the Radiation Safety Committee at Methodist Hospital, broad byproduct materials license no. 13-02063-01:

Larry Heck, M.D.	31.11, 35.100, 35.200, 35.300, 35.500
Eugene Van Hove, M.D.	31.11, 35.100, 35.200, 35.300, 35.500
Jerry Kight, M.D.	31.11, 35.100, 35.200, 35.300, 35.500
Dale Apodaca, M.D.	31.11, 35.100, 35.200, 35.300, 35.500
Newell Pugh, M.D.	35.400, Ir-192 HDR
David Ross, M.D.	35.400, Ir-192 HDR
Peter Garrett, M.D.	35.400, Ir-192 HDR
William Rate, M.D.	35.400, Ir-192 HDR
Tom Dugan, M.D.	35.400, Ir-192 HDR

The following RSI Radiologists are listed as Authorized Users on byproduct materials license no. 13-18992-01, Decatur County Memorial Hospital, Greensburg, Indiana:

Barbara Taylor, M.D.	31.11, 35.100, 35.200 (no Xenon-133)
David Brown, M.D.	31.11, 35.100, 35.200 (no Xenon-133)
Paul Peterson, M.D.	31.11, 35.100, 35.200 (no Xenon-133)
Gonzalo Chua, M.D.	31.11, 35.100, 35.200 (no Xenon-133)
Jerry Kight, M.D.	31.11, 35.100, 35.200 (no Xenon-133)
Larry Heck, M.D.	31.11, 35.100, 35.200 (no Xenon-133)
Eugene Van Hove, M.D.	31.11, 35.100, 35.200 (no Xenon-133)


The following RSI Radiologists are listed as Authorized Users on byproduct materials license no. 13-16622-01, Culver Union Hospital, Crawfordsville, Indiana:

Fred McFall, M.D.	31.11, 35.100, 35.200
David Brown, M.D.	31.11, 35.100, 35.200
Paul Peterson, M.D.	31.11, 35.100, 35.200
Gonzalo Chua, M.D.	31.11, 35.100, 35.200, 35.300 (no therapy)
Jerry Kight, M.D.	31.11, 35.100, 35.200, 35.300 (no therapy)
Larry Heck, M.D.	31.11, 35.100, 35.200, 35.300 (no therapy)
Eugene Van Hove, M.D.	31.11, 35.100, 35.200, 35.300 (no therapy)

Robert Haerr, M.D. and Edwin Watkins, M.D. are members of RSI and have been approved for 35.400 under other licenses, but I do not have those numbers available.

If you have any questions regarding this information, please let me know.

Sincerely,



Robert T. Anger, Jr., M.S., M.P.H., DABR  
Medical Nuclear Physicist/RSO

SEP 24 1996

Thomas A. Pence  
Radiation Safety Officer  
Riverview Hospital  
P.O. Box 220  
395 Westfield Road  
Noblesville, IN 46090

Dear Mr. Pence:

Enclosed is Amendment No. 12 to your NRC Material License No. 13-16286-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
  - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
  - b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

301738

4. Request and obtain a license amendment before you:
  - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;
  - b. Permit anyone, except individuals described CFR 35.13(b), to work as an authorized user under the license;
  - c. Change Radiation Safety Officers;
  - d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
  - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
  - f. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements,

T. Pence

-3-

prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By  
Evelyn R. Matson  
Nuclear Materials Licensing Branch

License No.: 13-16286-01

Docket No.: 030-10729

Enclosure: Amendment No. 12

DOCUMENT NAME: M:\03010729.CL6

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII <i>EM</i> <i>N</i>							
NAME	EMATSON:jaw							
DATE	09/17/96							

OFFICIAL RECORD COPY